When was Aton Pharma founded?

Aton Pharma was founded in 2001 and raised its 1st funding round 2 years after it was founded.

Where is Aton Pharma located?

Aton Pharma is headquartered in New York City, United States.

How many employees does Aton Pharma have?

As of Mar 31, 2026, the latest employee count at Aton Pharma is 9.

Is Aton Pharma a funded company?

Aton Pharma is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jan 10, 2003.

When was the latest funding round of Aton Pharma?

Aton Pharma's latest funding was a $***** Series A round on Jan 10, 2003, with participation from 1 investor. Its primary sector is Ophthalmology. In United States, the Ophthalmology sector has seen $748M in funding in 2026 to date.

Where does Aton Pharma rank among its competitors?

Aton Pharma ranks 836th amongst 2624 active competitors, of which 903 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Aton Pharma?

Aton Pharma's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Among them, Karyopharm secured the most recent funding round in March, 2026.

Aton Pharma - 2026 Company Profile, Team, Funding & Competitors

Q: Is Aton Pharma an acquired company?

Aton Pharma got acquired by Bausch Health on May 03, 2010.

Aton Pharma is an acquired company based in New York City (United States), founded in 2001 by Bhatt Parth. It operates as an US-based pharma company developing therapeutics for ophthalmic diseases, orphan diseases, etc.. Aton Pharma has raised $37M in funding. The company has 2624 active competitors, including 903 funded and 663 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines.

Company Details

Aton Pharma, is a US-based pharma company developing therapeutics for ophthalmic diseases, orphan diseases, etc. The company has products for metabolic, neurological, and cardiovascular diseases. Its products include timolol maleate ophthalmic gel forming solution for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The company was acquired by Valeant Pharma in May.2010 for $318M.

Website: atonrx.com
Email ID: *****@atonrx.com

Key Metrics

Founded Year

2001

Location

New York City, United States

Stage

Acquired

Total Funding

$37M in 1 round

Latest Funding Round

Series A, Jan 10, 2003, $*****

Investors

Aisling Capital & 4 more

Ranked

836^th among 2624 active competitors

Employee Count

9 as on Mar 31, 2026

Similar Companies

Annexon & 280 more

Exit Details

Acquired by Bausch Health (May 03, 2010)

View Aton Pharma's full profile

Aton Pharma is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Aton Pharma, Inc. CIN: 13-4120965 , United States, Active	Dec 31, 2000	-	-	-

Aton Pharma got acquired by Bausch Health on May 03, 2010 at an acquisition amount of $*****.

Click here to take a look at Aton Pharma's acquisition in detail

Aton Pharma has raised a total funding of $37M over 1 round. Its latest funding round was a Series A round on Jan 10, 2003 for $*****. 1 investor participated in its latest round. Aton Pharma has 5 institutional investors.

Here is the list of recent funding rounds of Aton Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 10, 2003	6322060	Series A	5722828	3191172	8646566	6944816

Access funding benchmarks and valuations. Sign up today!

View details of Aton Pharma's funding rounds and investors

The founders of Aton Pharma is Bhatt Parth.

Here are the details of Aton Pharma's key team members:

Bhatt Parth: Owner of Aton Pharma.

View details of Aton Pharma's Founder profiles and Board Members

Aton Pharma's employee count trend

Aton Pharma has 9 employees as of Mar 26. Here is Aton Pharma's employee count trend over the years:

Uncover Aton Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Aton Pharma include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Here is the list of Top 10 competitors of Aton Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
3rd	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 18 others	72/100
8th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 16 others	71/100
836th	Aton Pharma 2001, New York City (United States), Acquired	US-based pharma company developing therapeutics for ophthalmic diseases, orphan diseases, etc.	$37M	Aisling Capital, Spring Mountain Capital & 3 others	41/100